SYSMHC00023 |
SYSMHC00023_HLA-I-p_MM15 |
SYSMHC00023_20141210_QEp7_MiBa_SA_HLA-I-p_MM15_1_B_1.raw |
Human |
In vivo |
Skin |
Melanoma |
|
Metastatic |
|
class I |
HLA-A03:01,HLA-A68:01,HLA-B27:05,HLA-B35:03,HLA-C02:02,HLA-C04:01 |
27869121 |
native |
Immunoaffinity |
W6/32 |
Q-Exactive HF |
no-LC, Proxeon Biosystems, Thermo |
no |
DDA |
HCD |
2-30% ACN |
90 |
25 nL/min |
1 |
SYSMHC00023 |
SYSMHC00023_HLA-I-p_MM15 |
SYSMHC00023_20141210_QEp7_MiBa_SA_HLA-I-p_MM15_2_A_1.raw |
Human |
In vivo |
Skin |
Melanoma |
|
Metastatic |
|
class I |
HLA-A03:01,HLA-A68:01,HLA-B27:05,HLA-B35:03,HLA-C02:02,HLA-C04:01 |
27869121 |
native |
Immunoaffinity |
W6/32 |
Q-Exactive HF |
no-LC, Proxeon Biosystems, Thermo |
no |
DDA |
HCD |
2-30% ACN |
90 |
25 nL/min |
2 |
SYSMHC00023 |
SYSMHC00023_HLA-I-p_MM15 |
SYSMHC00023_20141210_QEp7_MiBa_SA_HLA-I-p_MM15_2_B_1.raw |
Human |
In vivo |
Skin |
Melanoma |
|
Metastatic |
|
class I |
HLA-A03:01,HLA-A68:01,HLA-B27:05,HLA-B35:03,HLA-C02:02,HLA-C04:01 |
27869121 |
native |
Immunoaffinity |
W6/32 |
Q-Exactive HF |
no-LC, Proxeon Biosystems, Thermo |
no |
DDA |
HCD |
2-30% ACN |
90 |
25 nL/min |
3 |
SYSMHC00023 |
SYSMHC00023_HLA-I-p_MM15 |
SYSMHC00023_20141210_QEp7_MiBa_SA_HLA-I-p_MM15_1_A_1.raw |
Human |
In vivo |
Skin |
Melanoma |
|
Metastatic |
|
class I |
HLA-A03:01,HLA-A68:01,HLA-B27:05,HLA-B35:03,HLA-C02:02,HLA-C04:01 |
27869121 |
native |
Immunoaffinity |
W6/32 |
Q-Exactive HF |
no-LC, Proxeon Biosystems, Thermo |
no |
DDA |
HCD |
2-30% ACN |
90 |
25 nL/min |
4 |
SYSMHC00023 |
SYSMHC00023_HLA-I-p_MM15 |
SYSMHC00023_20141210_QEp7_MiBa_SA_HLA-I-p_MM15_3_B_1.raw |
Human |
In vivo |
Skin |
Melanoma |
|
Metastatic |
|
class I |
HLA-A03:01,HLA-A68:01,HLA-B27:05,HLA-B35:03,HLA-C02:02,HLA-C04:01 |
27869121 |
native |
Immunoaffinity |
W6/32 |
Q-Exactive HF |
no-LC, Proxeon Biosystems, Thermo |
no |
DDA |
HCD |
2-30% ACN |
90 |
25 nL/min |
5 |
SYSMHC00023 |
SYSMHC00023_HLA-I-p_MM15 |
SYSMHC00023_20141210_QEp7_MiBa_SA_HLA-I-p_MM15_4_A_1.raw |
Human |
In vivo |
Skin |
Melanoma |
|
Metastatic |
|
class I |
HLA-A03:01,HLA-A68:01,HLA-B27:05,HLA-B35:03,HLA-C02:02,HLA-C04:01 |
27869121 |
native |
Immunoaffinity |
W6/32 |
Q-Exactive HF |
no-LC, Proxeon Biosystems, Thermo |
no |
DDA |
HCD |
2-30% ACN |
90 |
25 nL/min |
6 |
SYSMHC00023 |
SYSMHC00023_HLA-I-p_MM15 |
SYSMHC00023_20141210_QEp7_MiBa_SA_HLA-I-p_MM15_4_B_1.raw |
Human |
In vivo |
Skin |
Melanoma |
|
Metastatic |
|
class I |
HLA-A03:01,HLA-A68:01,HLA-B27:05,HLA-B35:03,HLA-C02:02,HLA-C04:01 |
27869121 |
native |
Immunoaffinity |
W6/32 |
Q-Exactive HF |
no-LC, Proxeon Biosystems, Thermo |
no |
DDA |
HCD |
2-30% ACN |
90 |
25 nL/min |
7 |
SYSMHC00023 |
SYSMHC00023_HLA-I-p_MM15 |
SYSMHC00023_20141210_QEp7_MiBa_SA_HLA-I-p_MM15_3_A_1.raw |
Human |
In vivo |
Skin |
Melanoma |
|
Metastatic |
|
class I |
HLA-A03:01,HLA-A68:01,HLA-B27:05,HLA-B35:03,HLA-C02:02,HLA-C04:01 |
27869121 |
native |
Immunoaffinity |
W6/32 |
Q-Exactive HF |
no-LC, Proxeon Biosystems, Thermo |
no |
DDA |
HCD |
2-30% ACN |
90 |
25 nL/min |
8 |
SYSMHC00023 |
SYSMHC00023_HLA-I-p_MM15 |
SYSMHC00023_20141208_QEp7_MiBa_SA_HLA-I-p_MM15_4_B.raw |
Human |
In vivo |
Skin |
Melanoma |
|
Metastatic |
|
class I |
HLA-A03:01,HLA-A68:01,HLA-B27:05,HLA-B35:03,HLA-C02:02,HLA-C04:01 |
27869121 |
native |
Immunoaffinity |
W6/32 |
Q-Exactive HF |
no-LC, Proxeon Biosystems, Thermo |
no |
DDA |
HCD |
2-30% ACN |
90 |
25 nL/min |
9 |
SYSMHC00023 |
SYSMHC00023_HLA-I-p_MM15 |
SYSMHC00023_20141208_QEp7_MiBa_SA_HLA-I-p_MM15_1_B.raw |
Human |
In vivo |
Skin |
Melanoma |
|
Metastatic |
|
class I |
HLA-A03:01,HLA-A68:01,HLA-B27:05,HLA-B35:03,HLA-C02:02,HLA-C04:01 |
27869121 |
native |
Immunoaffinity |
W6/32 |
Q-Exactive HF |
no-LC, Proxeon Biosystems, Thermo |
no |
DDA |
HCD |
2-30% ACN |
90 |
25 nL/min |
10 |
SYSMHC00023 |
SYSMHC00023_HLA-I-p_MM15 |
SYSMHC00023_20141208_QEp7_MiBa_SA_HLA-I-p_MM15_3_A.raw |
Human |
In vivo |
Skin |
Melanoma |
|
Metastatic |
|
class I |
HLA-A03:01,HLA-A68:01,HLA-B27:05,HLA-B35:03,HLA-C02:02,HLA-C04:01 |
27869121 |
native |
Immunoaffinity |
W6/32 |
Q-Exactive HF |
no-LC, Proxeon Biosystems, Thermo |
no |
DDA |
HCD |
2-30% ACN |
90 |
25 nL/min |
11 |
SYSMHC00023 |
SYSMHC00023_HLA-I-p_MM15 |
SYSMHC00023_20141208_QEp7_MiBa_SA_HLA-I-p_MM15_2_B.raw |
Human |
In vivo |
Skin |
Melanoma |
|
Metastatic |
|
class I |
HLA-A03:01,HLA-A68:01,HLA-B27:05,HLA-B35:03,HLA-C02:02,HLA-C04:01 |
27869121 |
native |
Immunoaffinity |
W6/32 |
Q-Exactive HF |
no-LC, Proxeon Biosystems, Thermo |
no |
DDA |
HCD |
2-30% ACN |
90 |
25 nL/min |
12 |
SYSMHC00023 |
SYSMHC00023_HLA-I-p_MM15 |
SYSMHC00023_20141208_QEp7_MiBa_SA_HLA-I-p_MM15_2_A.raw |
Human |
In vivo |
Skin |
Melanoma |
|
Metastatic |
|
class I |
HLA-A03:01,HLA-A68:01,HLA-B27:05,HLA-B35:03,HLA-C02:02,HLA-C04:01 |
27869121 |
native |
Immunoaffinity |
W6/32 |
Q-Exactive HF |
no-LC, Proxeon Biosystems, Thermo |
no |
DDA |
HCD |
2-30% ACN |
90 |
25 nL/min |
13 |
SYSMHC00023 |
SYSMHC00023_HLA-I-p_MM15 |
SYSMHC00023_20141208_QEp7_MiBa_SA_HLA-I-p_MM15_4_A.raw |
Human |
In vivo |
Skin |
Melanoma |
|
Metastatic |
|
class I |
HLA-A03:01,HLA-A68:01,HLA-B27:05,HLA-B35:03,HLA-C02:02,HLA-C04:01 |
27869121 |
native |
Immunoaffinity |
W6/32 |
Q-Exactive HF |
no-LC, Proxeon Biosystems, Thermo |
no |
DDA |
HCD |
2-30% ACN |
90 |
25 nL/min |
14 |
SYSMHC00023 |
SYSMHC00023_HLA-I-p_MM15 |
SYSMHC00023_20141208_QEp7_MiBa_SA_HLA-I-p_MM15_1_A.raw |
Human |
In vivo |
Skin |
Melanoma |
|
Metastatic |
|
class I |
HLA-A03:01,HLA-A68:01,HLA-B27:05,HLA-B35:03,HLA-C02:02,HLA-C04:01 |
27869121 |
native |
Immunoaffinity |
W6/32 |
Q-Exactive HF |
no-LC, Proxeon Biosystems, Thermo |
no |
DDA |
HCD |
2-30% ACN |
90 |
25 nL/min |
15 |